264 results
D
KA
Kineta Inc
20 Oct 23
$2.89 mm in options / securities to be acquired, 1 investor
1:04pm
in all instances or due to the nature of the offering that is the subject of this Form D, States cannot
routinely require offering materials under
8-K
EX-10.1
KA
Kineta Inc
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified … and effect as if such payment had not been made or such enforcement or setoff had not occurred.
5.17Independent Nature of Purchasers’ Obligations and Rights
424B5
saqtvoohnt799sk
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-10.1
a5gvx7ye5n
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
2sm6dc5m5e8ctnlj6
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
ymcfsmti 1esf2g19h7p
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
D
5v4iswns8f1w
29 Dec 22
$30.00 mm in equity, sold $7.50 mm, 17 investors
3:12pm
8-K
EX-99.6
50gpcsls
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
yl8u6pp80
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
yc37iovd oqsh07n2e4
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-3.3
lhg835386vtn0x
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.1
0s1b9
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
1r2r89e5b c9vd
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
72f9ea8pegc9vn 6nw6r
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm